This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

7 Nov 2011

Alios BioPharma & Versitech Sign for Influenza Therapy

The two companies have announced an exclusive worldwide licensing agreement to advance the research, development, manufacture and commercialization of novel medicines to treat influenza infection.

California-based biotech Alios BioPharma has signed an exclusive worldwide licensing deal with Versitech, a wholly-owned subsidiary of the University of Hong Kong, to develop, manufacture and market medication to combat influenza viruses.


The companies have also entered into two other influenza-related, non-exclusive licence agreements and a sponsored research agreement.


Alios will sponsor collaborative research at the University of Hong Kong, as Versitech is its technology transfer company.


Alios BioPharma president and CEO Lawrence Blatt said that the compounds and technology derived from the deal will provide key therapeutic options to help improve patients infected from influenza

Related News